Combined Metabolic Activators decrease liver steatosis by activating mitochondrial metabolism in a Golden Syrian hamster study
Yang, H.; Mayneris-Perxachs, J.; Boque, N.; Bas, J. M. d.; Arola, L.; Yuan, M.; Turkez, H.; Uhlen, M.; Boren, J.; Zhang, C.; Mardinoglu, A.; Caimari, A.
Show abstract
The prevalence of non-alcohol fatty liver disease (NAFLD), defined as the livers excessive fat accumulation, continues to increase dramatically. We have recently revealed the molecular mechanism underlying NAFLD using in-depth multi-omics profiling and identified that combined metabolic activators (CMA) could be administered to decrease the amount of hepatic steatosis (HS) in mouse model and NAFLD patients based on systems analysis. Here, we investigated the effects of a CMA including L-carnitine, N-acetyl-l-cysteine, nicotinamide riboside and betaine on a Golden Syrian hamster NAFLD model fed with HFD, and found that HS was decreased with the administration of CMA. To explore the mechanisms involved in the clearance HS, we generated liver transcriptomics data before and after CMA administration, and integrated these data using liver-specific genome-scale metabolic model of liver tissue. We systemically determined the molecular changes after the supplementation of CMAs and found that it activates mitochondria in the liver tissue by modulating the global fatty acid, amino acids, antioxidant and folate metabolism.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.